The role of signal transducers and activators of transcription in T inflammatory bowel diseases
Corresponding Author
Dr. Jonas Mudter
1st Medical Clinic, Johannes Gutenberg University of Mainz, Germany
Laboratory of Immunology, 1st Medical Clinic, University of Mainz, 55131 Mainz, GermanySearch for more papers by this authorMarkus F. Neurath
1st Medical Clinic, Johannes Gutenberg University of Mainz, Germany
Search for more papers by this authorCorresponding Author
Dr. Jonas Mudter
1st Medical Clinic, Johannes Gutenberg University of Mainz, Germany
Laboratory of Immunology, 1st Medical Clinic, University of Mainz, 55131 Mainz, GermanySearch for more papers by this authorMarkus F. Neurath
1st Medical Clinic, Johannes Gutenberg University of Mainz, Germany
Search for more papers by this authorAbstract
Signal transducers and activators of transcription (STAT) proteins are intracellular effector molecules of cytokine-modulated signaling. On the one hand, they play an important role in hematopoiesis and the development of the human immune system. STAT transcription factors are necessary for embryogenesis and the maintenance of the mammalian immune response. In the adult, STAT signaling is responsible for T-cell polarization toward interferon γ–secreting Th1 T cells or interleukin 4–producing Th2 cells. On the other hand, these proteins are involved in the regulation of T-cell survival. STAT activation is strongly associated with tyrosine phosphorylation by tyrosine kinases, namely Jak1, Jak2, Jak3, and Tyk2. Counterregulatory mechanisms protecting from overwhelming STAT activation are represented by protein inhibitors of activated STATs and the SOCS family proteins. Because STAT proteins are key response elements of cytokine-induced T-cell activation, the characterization of STAT proteins is one step to elucidate disturbed T-cell function in inflammatory bowel disease. In particular, an activation of STAT-4 and STAT-3 in T cells seems to play a key pathogenic role in Crohn's disease.
References
- 1 Darnell Jr. JE STATs and gene regulation. Science 1997; 277: 1630–5.
- 2 Aaronson DS, Horvath CM. A road map for those who know JAK-STAT. Science 2002; 296: 1653–5.
- 3 Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biologic function. Biochem J 1994; 300: 281–90.
- 4 Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473–80.
- 5 Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 1999; 18: 1549–58.
- 6 Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 2001; 73: 271–7.
- 7 Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13: 211–7.
- 8 Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373–83.
- 9 Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385–95.
- 10 Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93: 397–409.
- 11 Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13: 561–71.
- 12 Wen R, Wang D, McKay C, et al. Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol Cell Biol 2001; 21: 678–89.
- 13 Candotti F. The potential for therapy of immune disorders with gene therapy. Pediatr Clin North Am 2000; 47: 1389–407.
- 14 Candotti F, Notarangelo L, Visconti R, et al. Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J Clin Invest 2002; 109: 1261–9.
- 15 Leonard WJ, O'Shea JJ. Jaks and STATs: biologic implications. Annu Rev Immunol 1998; 16: 293–322.
- 16 Darnell Jr. JE Phosphotyrosine signaling and the single cell: metazoan boundary. Proc Natl Acad Sci U S A 1997; 94: 11767–9.
- 17 Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1–24.
- 18 McBride KM, McDonald C, Reich NC. Nuclear export signal located within the DNA-binding domain of the STAT1transcription factor. EMBO J 2000; 19: 6196–206.
- 19 Vinkemeier U, Moarefi I, Darnell Jr, JE et al. Structure of the amino-terminal protein interaction domain of STAT-4. Science 1998; 279: 1048–52.
- 20 Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431–42.
- 21 Durbin JE, Hackenmiller R, Simon MC, et al. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84: 443–50.
- 22 Park C, Li S, Cha E, et al. Immune response in Stat2 knockout mice. Immunity 2000; 13: 795–804.
- 23 Takeda K, Kaisho T, Yoshida N, et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998; 161: 4652–60.
- 24 Mudter J, Wirtz S, Galle PR, et al. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology 2002; 70: 170–6.
- 25 Thierfelder WE, van Deursen JM, Yamamoto K, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382: 171–4.
- 26 Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996; 380: 627–30.
- 27 Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 630–3.
- 28 Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313–9.
- 29 Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin Invest 2002; 109: 1279–83.
- 30 Feldman GM, Rosenthal LA, Liu X, et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 1997; 90: 1768–76.
- 31 Imada K, Bloom ET, Nakajima H, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 1998; 188: 2067–74.
- 32 Kieslinger M, Woldman I, Moriggl R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000; 14: 232–44.
- 33 Snow JW, Abraham N, Ma MC, et al. STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 2002; 99: 95–101.
- 34 Strous GJ, van Kerkhof P, Govers R, et al. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J 1996; 15: 3806–12.
- 35 Zhang JG, Metcalf D, Rakar S, et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci U S A 2001; 98: 13261–5.
- 36 Wang D, Stravopodis D, Teglund S, et al. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 1996; 16: 6141–8.
- 37 Azam M, Lee C, Strehlow I, et al. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity 1997; 6: 691–701.
- 38 Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803–5.
- 39 Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998; 95: 10626–31.
- 40 Kile BT, Nicola NA, Alexander WS. Negative regulators of cytokine signaling. Int J Hematol 2001; 73: 292–8.
- 41 Hanada T, Kinjyo I, Inagaki-Ohara K, et al. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev Physiol Biochem Pharmacol 2003; 29: 29.
- 42 Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921–4.
- 43 Greenhalgh CJ, Bertolino P, Asa SL, et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 2002; 16: 1394–406.
- 44 Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471–81.
- 45 Shanahan F. Crohn's disease. Lancet 2002; 359: 62–9.
- 46 Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002; 8: 567–73.
- 47 Schreiber S, Rosenstiel P, Hampe J, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002; 51: 379–85.
- 48 Mazzarella G, MacDonald TT, Salvati VM, et al. Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions. Am J Pathol 2003; 162: 1845–55.
- 49 Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3: 549–57.
- 50 Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195: 1129–43.
- 51 Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583–8.
- 52 Lovato P, Brender C, Agnholt J, et al. Constitutive Stat3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 3: 3.
- 53 Jacobson NG, Szabo SJ, Weber-Nordt RM, et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 1995; 181: 1755–62.
- 54 Nishikomori R, Usui T, Wu CY, et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002; 169: 4388–98.
- 55 Levy DE, Darnell Jr. JE Stats: transcriptional control and biologic impact. Nat Rev Mol Cell Biol 2002; 3: 651–62.
- 56 Palmer EM, Farrokh-Siar L, Maguire van Seventer J, et al. IL-12 decreases activation-induced cell death in human naive Th cells costimulated by intercellular adhesion molecule-1: I. IL-12 alters caspase processing and inhibits enzyme function. J Immunol 2001; 167: 749–58.
- 57 Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117: 1078–88.
- 58 Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281–90.